Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes
The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra-long effect. However, there are few published studies in children and adolescents. The first aim was to compare HbA1c levels in children and adolescents who received degludec from onset, to age/gender matched controls with oth
